Literature DB >> 22298980

Antibiotics for the treatment of irritable bowel syndrome.

Robert J Basseri1, Stacy Weitsman, Gillian M Barlow, Mark Pimentel.   

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with an estimated worldwide prevalence of 10-20%. IBS can be associated with severe gastrointestinal symptoms, including abdominal pain, bloating, and altered bowel function. Although the causes of IBS remain undefined, recent research has increasingly suggested roles for gut flora in IBS. These roles involve postinfectious IBS, which can occur after a single episode of acute gastroenteritis, and small intestinal bacterial overgrowth, in which elevated populations of aerobic and anaerobic bacteria cause abdominal pain and altered bowel function. More recently, potential roles for methanogens in contributing to IBS subtypes have also been identified. In this paper, we review the different mechanisms by which gut flora may contribute to IBS and also discuss the efficacy and safety of various antibiotic therapies for treating IBS symptoms.

Entities:  

Keywords:  Irritable bowel syndrome; antibiotics; neomycin; re-treatment; rifaximin

Year:  2011        PMID: 22298980      PMCID: PMC3264894     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  88 in total

1.  Rifaximin intake leads to emergence of rifampin-resistant staphylococci.

Authors:  Thomas Valentin; Eva Leitner; Angelika Rohn; Ines Zollner-Schwetz; Martin Hoenigl; Helmut J F Salzer; Robert Krause
Journal:  J Infect       Date:  2010-11-10       Impact factor: 6.072

2.  Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders.

Authors: 
Journal:  J Gastrointestin Liver Dis       Date:  2006-09       Impact factor: 2.008

Review 3.  The indigenous gastrointestinal microflora.

Authors:  R D Berg
Journal:  Trends Microbiol       Date:  1996-11       Impact factor: 17.079

4.  Small intestine bacterial overgrowth.

Authors:  C E King; P P Toskes
Journal:  Gastroenterology       Date:  1979-05       Impact factor: 22.682

5.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

6.  Methane production during lactulose breath test is associated with gastrointestinal disease presentation.

Authors:  Mark Pimentel; Andrew G Mayer; Sandy Park; Evelyn J Chow; Aliya Hasan; Yuthana Kong
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

7.  Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

Authors:  M Majewski; R W McCallum
Journal:  Adv Med Sci       Date:  2007       Impact factor: 3.287

8.  The degree of breath methane production in IBS correlates with the severity of constipation.

Authors:  Soumya Chatterjee; Sandy Park; Kimberly Low; Yuthana Kong; Mark Pimentel
Journal:  Am J Gastroenterol       Date:  2007-04       Impact factor: 10.864

9.  Carbohydrate malabsorption: quantification by methane and hydrogen breath tests.

Authors:  J J Rumessen; I Nordgaard-Andersen; E Gudmand-Høyer
Journal:  Scand J Gastroenterol       Date:  1994-09       Impact factor: 2.423

10.  Development of the human infant intestinal microbiota.

Authors:  Chana Palmer; Elisabeth M Bik; Daniel B DiGiulio; David A Relman; Patrick O Brown
Journal:  PLoS Biol       Date:  2007-06-26       Impact factor: 8.029

View more
  21 in total

Review 1.  Gas and the microbiome.

Authors:  Mark Pimentel; Ruchi Mathur; Christopher Chang
Journal:  Curr Gastroenterol Rep       Date:  2013-12

2.  Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma.

Authors:  Xiaoying Ma; Heju Wang; Peng Zhang; Lin Xu; Zibin Tian
Journal:  Turk J Gastroenterol       Date:  2019-02       Impact factor: 1.852

Review 3.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 4.  Irritable bowel syndrome: a concise review of current treatment concepts.

Authors:  Geoffrey C Wall; Ginelle A Bryant; Michelle M Bottenberg; Erik D Maki; Andrew R Miesner
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

5.  Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer.

Authors:  Lihua Deng; Yang Liu; Dongsheng Zhang; Yuan Li; Lin Xu
Journal:  Mol Clin Oncol       Date:  2016-03-07

Review 6.  Antibiotics for irritable bowel syndrome: rationale and current evidence.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Curr Gastroenterol Rep       Date:  2012-10

Review 7.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

8.  Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome.

Authors:  Aiysha Thompson; Dilruba Meah; Nadia Ahmed; Rebecca Conniff-Jenkins; Emma Chileshe; Chris O Phillips; Tim C Claypole; Dan W Forman; Paula E Row
Journal:  BMC Complement Altern Med       Date:  2013-11-28       Impact factor: 3.659

9.  Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

Authors:  P Schoenfeld; M Pimentel; L Chang; A Lembo; W D Chey; J Yu; C Paterson; E Bortey; W P Forbes
Journal:  Aliment Pharmacol Ther       Date:  2014-04-03       Impact factor: 8.171

10.  Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3.

Authors:  Enzo Vicari; Sandro La Vignera; Roberto Castiglione; Rosita A Condorelli; Lucia O Vicari; Aldo E Calogero
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.